Advertisement
PTC Therapeutics Granted Marketing Authorization By EU For Upstaza To Treat AADC Deficiency
(RTTNews) - PTC Therapeutics, Inc. (PTCT) announced Wednesday that Upstaza (eladocagene exuparvovec) was granted marketing authorization by the European Commission. Upstaza is the first approved disease-modifying treatment for aromatic L-amino acid decarboxylase (AADC) deficiency and the first marketed gene therapy directly infused into the brain. It is approved for patients 18 months and older.
Upstaza is a one-time gene replacement therapy indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of AADC deficiency with a severe phenotype.
The marketing authorization is applicable to all 27 European Union member states, as well as Iceland, Norway and Liechtenstein.
For More Such Health News, visit rttnews.com
read more
FDA Approves PTC's Kebilidi As First Gene Therapy To Treat AADC Deficiency
The U.S. Food and Drug Administration approved PTC Therapeutics, Inc.'s Kebilidi (eladocagene exuparvovec-tneq) gene therapy for the treatment of aromatic L-amino acid decarboxylase or AADC deficiency. Kebilidi is the first FDA-approved gene therapy for the deficiency. PTC shares gained around 8.5 percent in the extended trading on the Nasdaq on Thursday.
RTTNews
|
179 dni temu
PTC Therapeutics Says European Commission Returns Translarna Opinion To CHMP For Re-evaluation
PTC Therapeutics, Inc. (PTCT) announced Monday that the European Commission (EC) has decided not to adopt the CHMP's negative opinion of January 24, 2024 on the annual renewal of the conditional marketing authorization of Translarna (ataluren) and has returned the opinion to the CHMP for re-evaluation.
RTTNews
|
358 dni temu
U.S. Consumer Prices Rise 0.2% In April, Slightly Less Than Expected
Consumer prices in the U.S. rose by slightly less than expected in the month of April, according to a report released by the Labor Department on Tuesday. The Labor Department said its consumer price index inched up by 0.2 percent in April after edging down by 0.1 percent in March. Economists had expected consumer prices to rise by 0.3 percent.
RTTNews
|
3g 21 minut temu
Bayer Q1 Results Down, Sees Pharma Results At Top End Of View; Stock Gains
Bayer AG on Tuesday confirmed its currency-adjusted 2025 targets after reporting lower earnings in its first quarter with slightly lower sales. The quarterly results reflected weak results in the Crop Science Division, despite growth in Pharmaceuticals and Consumer Health segments. Shares of the Pharmaceutical and life sciences major were gaining around 6 percent on the XETRA in Germany.
RTTNews
|
4g 14 minut temu
U.S. Consumer Prices Rise Slightly Less Than Expected In April
Consumer prices in the U.S. rose by slightly less than expected in the month of April, according to a report released by the Labor Department on Tuesday.
RTTNews
|
4g 25 minut temu
Bay Street May Open On Subdued Note; U.S. Inflation Data In Focus
Futures indicate a somewhat subdued start for the Canadian market on Tuesday. However, U.S. consumer price inflation data is likely to make an impact on stocks as the inflation numbers from the world's largest economy could give some clues about the Federal Reserve's policy moves.
RTTNews
|
4g 35 minut temu
UK Labor Market Cools Down In Q1
The UK unemployment rate edged up and wage growth softened in the first quarter ahead of the rise in payroll taxes, official data revealed on Tuesday. The unemployment rate rose to 4.5 percent in the three months to March, in line with expectations, from 4.4 percent in the three months to February, the Office for National Statistics reported.
RTTNews
|
4g 36 minut temu
FTSE 100 Modestly Higher In Cautious Trade
U.K. stocks are up in positive territory a little past noon on Tuesday, although gains are just modest as investors make cautious moves, choosing to wait for more news on the economic as well as trade front.
RTTNews
|
5g 35 minut temu
